RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eiger BioPharmaceuticals Stock

Eiger BioPharmaceuticals ROA 2024

Eiger BioPharmaceuticals ROA

-1.93

Ticker

EIGR

ISIN

US28249U1051

WKN

A2AF9X

In 2024, Eiger BioPharmaceuticals's return on assets (ROA) was -1.93, a 139.6% increase from the -0.81 ROA in the previous year.

Eiger BioPharmaceuticals Aktienanalyse

What does Eiger BioPharmaceuticals do?

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Eiger BioPharmaceuticals's Return on Assets (ROA)

Eiger BioPharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Eiger BioPharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Eiger BioPharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Eiger BioPharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Eiger BioPharmaceuticals stock

What is the Return on Assets (ROA) of Eiger BioPharmaceuticals this year?

The Return on Assets (ROA) of Eiger BioPharmaceuticals is -1.93 undefined this year.

What was the ROA of Eiger BioPharmaceuticals compared to the previous year?

The ROA of Eiger BioPharmaceuticals has increased by 139.6% compared to the previous year.

What consequences do high ROA have for investors of Eiger BioPharmaceuticals?

A high ROA is advantageous for investors of Eiger BioPharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Eiger BioPharmaceuticals?

A low ROA can be unfavorable for investors of Eiger BioPharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Eiger BioPharmaceuticals affect the company?

An increase in ROA of Eiger BioPharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Eiger BioPharmaceuticals impact the company?

A reduction in the ROA of Eiger BioPharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Eiger BioPharmaceuticals?

Some factors that can influence the ROA of Eiger BioPharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Eiger BioPharmaceuticals important for investors?

The ROA of Eiger BioPharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Eiger BioPharmaceuticals take to improve ROA?

To improve ROA, Eiger BioPharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eiger BioPharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.